Feng Roger Luo, Jian Ding, Helen X Chen, Hao Liu, Man-Cheong Fung, Maria Koehler, Jean Pierre Armand, Lei Jiang, Xiao Xu, Ge Zhang, Li Xu, Pascal Qian, Li Yan
{"title":"突破性癌症药物及其对中国新药研发的影响：美国华人抗癌协会（USCACA）和中国临床肿瘤学会（CSCO）在第 17 届 CSCO 年会上的联合会议报告。","authors":"Feng Roger Luo, Jian Ding, Helen X Chen, Hao Liu, Man-Cheong Fung, Maria Koehler, Jean Pierre Armand, Lei Jiang, Xiao Xu, Ge Zhang, Li Xu, Pascal Qian, Li Yan","doi":"10.5732/cjc.014.10246","DOIUrl":null,"url":null,"abstract":"<p><p>The US Chinese Anti-Cancer Association (USCACA) teamed up with Chinese Society of Clinical Oncology (CSCO) to host a joint session at the17th CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. With a focus on breakthrough cancer medicines, the session featured innovative approaches to evaluate breakthrough agents and established a platform to interactively share successful experiences from case studies of 6 novel agents from both the United States and China. The goal of the session is to inspire scientific and practical considerations for clinical trial design and strategy to expedite cancer drug development in China. A panel discussion further provided in-depth advice on advancing both early and full development of novel cancer medicines in China. </p>","PeriodicalId":10034,"journal":{"name":"癌症","volume":"33 12","pages":"620-4"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/10/cjc-33-12-620.PMC4308658.pdf","citationCount":"0","resultStr":"{\"title\":\"Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting.\",\"authors\":\"Feng Roger Luo, Jian Ding, Helen X Chen, Hao Liu, Man-Cheong Fung, Maria Koehler, Jean Pierre Armand, Lei Jiang, Xiao Xu, Ge Zhang, Li Xu, Pascal Qian, Li Yan\",\"doi\":\"10.5732/cjc.014.10246\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The US Chinese Anti-Cancer Association (USCACA) teamed up with Chinese Society of Clinical Oncology (CSCO) to host a joint session at the17th CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. With a focus on breakthrough cancer medicines, the session featured innovative approaches to evaluate breakthrough agents and established a platform to interactively share successful experiences from case studies of 6 novel agents from both the United States and China. The goal of the session is to inspire scientific and practical considerations for clinical trial design and strategy to expedite cancer drug development in China. A panel discussion further provided in-depth advice on advancing both early and full development of novel cancer medicines in China. </p>\",\"PeriodicalId\":10034,\"journal\":{\"name\":\"癌症\",\"volume\":\"33 12\",\"pages\":\"620-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/10/cjc-33-12-620.PMC4308658.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"癌症\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5732/cjc.014.10246\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/11/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5732/cjc.014.10246","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/11/21 0:00:00","PubModel":"Epub","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting.
The US Chinese Anti-Cancer Association (USCACA) teamed up with Chinese Society of Clinical Oncology (CSCO) to host a joint session at the17th CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. With a focus on breakthrough cancer medicines, the session featured innovative approaches to evaluate breakthrough agents and established a platform to interactively share successful experiences from case studies of 6 novel agents from both the United States and China. The goal of the session is to inspire scientific and practical considerations for clinical trial design and strategy to expedite cancer drug development in China. A panel discussion further provided in-depth advice on advancing both early and full development of novel cancer medicines in China.
期刊介绍：
In July 2008, Landes Bioscience and Sun Yat-sen University Cancer Center began co-publishing the international, English-language version of AI ZHENG or the Chinese Journal of Cancer (CJC). CJC publishes original research, reviews, extra views, perspectives, supplements, and spotlights in all areas of cancer research. The primary criteria for publication in CJC are originality, outstanding scientific merit, and general interest. The Editorial Board is composed of members from around the world, who will strive to maintain the highest standards for excellence in order to generate a valuable resource for an international readership.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
